NASDAQ: IMMXImmix Biopharma Inc Stock
$2.13-0.17 (-7.39%)
Updated Apr 24, 2024
IMMX Price
$2.13
Fair Value Price
$1.01
Market Cap
$56.22M
52 Week Low
$1.40
52 Week High
$7.75
P/E
-2.39x
P/B
3.43x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$15.43M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.23
Operating Cash Flow
-$11M
Beta
0.93
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
IMMX Overview
Immix Biopharma, Inc. is developing tissue-specific therapeutics to treat cancer and inflammatory diseases. The company's pipeline includes IMX-110, in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors, IMX-111, a tissue-specific biologic for the treatment of colorectal cancers, and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. Immix Biopharma was incorporated in 2012 and is headquartered in Los Angeles, CA.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how IMMX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
IMMX ($2.13) is overvalued by 110.95% relative to our estimate of its Fair Value price of $1.01 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
IMMX ($2.13) is not significantly undervalued (110.95%) relative to our estimate of its Fair Value price of $1.01 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
IMMX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more IMMX due diligence checks available for Premium users.
Be the first to know about important IMMX news, forecast changes, insider trades & much more!
IMMX News
Valuation
IMMX fair value
Fair Value of IMMX stock based on Discounted Cash Flow (DCF)
Price
$2.13
Fair Value
$1.01
Overvalued by
110.95%
IMMX ($2.13) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
IMMX ($2.13) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
IMMX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
IMMX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.39x
Industry
15.69x
Market
41.27x
IMMX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.43x
Industry
5.86x
IMMX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
IMMX's financial health
Profit margin
Revenue
$0.0
Net Income
-$5.1M
Profit Margin
0%
IMMX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$19.9M
Liabilities
$3.7M
Debt to equity
0.23
IMMX's short-term assets ($19.79M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
IMMX's short-term assets ($19.79M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
IMMX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.7M
Investing
-$13.2k
Financing
$586.7k
IMMX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
IMMX vs Biotech Stocks
Immix Biopharma Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.